IP Library Granted Patent US 11,560,378
Granted Patent B2
US 11,560,378 · App. 17/108,544 · Granted Jan 24, 2023

Treatment of osteoarthritis

Inventors: John Hood (San Diego, CA); David Mark Wallace (San Diego, CA); Sunil Kumar KC (San Diego, CA); Yusuf Yazici (La Jolla, CA); Christopher Swearingen (San Marcos, CA); Luis A Dellamary (San Marcos, CA)
Assignee: BioSplice Therapeutics, Inc.
C07D471/04A61K9/0019A61K31/444A61K31/4545A61K31/496A61K31/5377A61P19/02A61P29/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,560,378
App. No.
17/108,544
Granted
Jan 24, 2023
Kind
B2
Abstract

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Claims (9)

1. A process for preparing a polymorph of a compound of Formula (I):

wherein the polymorph is Form 1 and has an X-ray powder diffraction pattern comprising peaks at ° 2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2; wherein the process comprises drying a compound of Formula (I) to Form 1.

2. The process of claim 1 , wherein the compound of Formula (I) comprises a mixture of a non-stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and Form 1.

3. The process of claim 1 , wherein the process comprises reslurrying the compound of Formula (I) in a solvent to generate Form 1; wherein the solvent is selected from the group consisting of methanol, toluene, heptane, dichloromethane, water, and mixtures thereof.

4. The process of claim 2 , wherein the process comprises reslurrying the compound of Formula (I) in a solvent to generate Form 1; wherein the solvent is selected from the group consisting of methanol, toluene, heptane, dichloromethane, water, and mixtures thereof.

5. The process of claim 1 , wherein the process comprises reslurrying the compound of Formula (I) in water and a solvent to generate Form 1; wherein the solvent is selected from the group consisting of acetonitrile, methanol, ethyl acetate, methyl tert-butyl ether, isopropyl alcohol, methyl acetate, methyl isobutyl ketone, dichloromethane, n-butyl acetate, heptane, and n-butanol.

6. The process of claim 2 , wherein the process comprises reslurrying the compound of Formula (I) in water and a solvent to generate Form 1; wherein the solvent is selected from the group consisting of acetonitrile, methanol, ethyl acetate, methyl tert-butyl ether, isopropyl alcohol, methyl acetate, methyl isobutyl ketone, dichloromethane, n-butyl acetate, heptane, and n-butanol.

7. The process of claim 5 , wherein the water is present in an amount of about 5% by weight of the total amount of water and solvent.

8. The process of claim 6 , wherein the water is present in an amount of about 5% by weight of the total amount of water and solvent.

Assignments (3)
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055694/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2020
From: HOOD, JOHN; WALLACE, DAVID MARK; KC, SUNIL KUMAR; YAZICI, YUSUF; SWEARINGEN, CHRISTOPHER; DELLAMARY, LUIS A.
To: SAMUMED, LLC
Reel/Frame 054542/0569 →
Continuity (5)
Division 16710099 · Dec 11, 2019
Continuation 15773951
Provisional Application 62303168 · Mar 3, 2016
Provisional Application 62252332 · Nov 6, 2015
Related Publication 20210292318A1 · Sep 23, 2021